Eculizumab in Adolescent Patients with Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study

This study evaluated the efficacy and safety of eculizumab, a terminal complement C5 inhibitor.

Source: Pediatric Neurology - April 25, 2024 Category: Neurology Authors: John F. Brandsema, Matthew Ginsberg, Hideki Hoshino, Masakazu Mimaki, Satoru Nagata, Vamshi K. Rao, Katherine Ruzhansky, Niraja Suresh, Emmanuelle Tiongson, Hideo Yamanouchi, Glen Frick, Eden Hicks, Serena Liao, James F. Howard, MG 303 Study Group Tags: Research Paper Source Type: research